A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging

Trial Profile

A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs Plozalizumab (Primary)
  • Indications Arteriosclerosis
  • Focus Pharmacodynamics
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Dec 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
    • 13 Nov 2015 Planned initiation date changed from 1 May 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top